MorphaBond ER + Comparator Drug
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Baseline Epidemiologic Assessment
Conditions
Baseline Epidemiologic Assessment
Trial Timeline
Oct 16, 2017 → Dec 31, 2020
NCT ID
NCT04033094About MorphaBond ER + Comparator Drug
MorphaBond ER + Comparator Drug is a pre-clinical stage product being developed by Daiichi Sankyo for Baseline Epidemiologic Assessment. The current trial status is completed. This product is registered under clinical trial identifier NCT04033094. Target conditions include Baseline Epidemiologic Assessment.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04033094 | Pre-clinical | Completed |
Competing Products
1 competing product in Baseline Epidemiologic Assessment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Capivasertib + Fulvestrant injection | AstraZeneca | Phase 2 | 52 |